NuGen Welcomes Liang Lin as New CEO: A Strategic Move for Global Growth

NuGen Medical Devices Inc. (TSXV: NGMD) has announced the appointment of Liang Lin as its new Chief Executive Officer (CEO), effective January 15, 2025. Lin, who joined NuGen's board in September 2024 following Sol-Millennium Medical Group's (SolM) strategic investment, brings extensive experience in the medical device sector, particularly in expanding international operations and strategic acquisitions. This appointment aligns with NuGen's strategic goals for 2025, focusing on global sales growth and meeting anticipated InsuJet™ production demands.

Liang Lin's appointment as CEO of NuGen Medical Devices is a strategic move that aligns with the company's goals for 2025. Lin's extensive experience in the medical device sector, particularly in expanding international operations and strategic acquisitions, will be crucial in driving global sales growth and meeting anticipated InsuJet™ production demands. As the founder and CEO of Sol-Millennium Medical Group (SolM), Lin has demonstrated success in expanding international footprints, including offices across Europe and the Middle East, and investing in R&D facilities in Asia and Europe. This commitment to R&D has enabled SolM to build a robust pipeline of innovative products poised to make a significant impact on the medical device industry.

Under Liang's dynamic leadership, SolM has made significant strides in expanding its international footprint. The organization has successfully penetrated the North American and Brazilian markets through strategic acquisitions, including Inviro Medical Inc. and Medica Brazil. Additionally, SolM has established offices across Europe and the Middle East, allowing the company to address a diverse range of healthcare needs and adapt to the unique challenges of various healthcare systems. To support its ambitious growth objectives, SolM has invested heavily in research and development, creating state-of-the-art facilities in both Asia and Europe. This commitment to R&D has enabled the company to build a robust pipeline of innovative products poised to make a significant impact on the medical device industry.

Liang will leverage his extensive knowledge and experience in the medical device field to drive innovation and growth at NuGen. His thorough understanding of industry trends, regulatory requirements, and technological advancements will enable the company to navigate the complexities of the market effectively. With his guidance, NuGen is expected to flourish, capitalizing on new opportunities and expanding its product offerings. Liang's strong leadership abilities position him to inspire and energize the team at NuGen, promoting a culture of collaboration and excellence.



In conclusion, Liang Lin's appointment as CEO of NuGen Medical Devices is a strategic move that aligns with the company's goals for 2025. His extensive experience in the medical device sector, particularly in expanding international operations and strategic acquisitions, will be crucial in driving global sales growth and meeting anticipated InsuJet™ production demands. NuGen's board of directors welcomes Liang to his new role, confident that his industry expertise and leadership style will foster innovation and growth at the company.